EGFR and breast carcinoma: Moreover, STAT3 is a well-known key pathway downstreamer of EGFR and a promoter to the epithelial to mesenchymal transition (EMT) in breast cancer [26], through which Anxa 2 promotes EMT in dependence on STAT3 pathway [27].